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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause
of disability and death. The most common cause of COPD is smoking. There is
evidence suggesting that genetic factors influence COPD susceptibility and vari-
ants in several candidate genes have been significantly associated with COPD.
In this study, we aimed to investigate the possible association of the TNF-α
–308, SPB+1580, IL-13 –1055 gene polymorphisms and latent adenovirus C infec-
tion with COPD in an Egyptian population.
Material and methods: Our study included 115 subjects (75 smokers with COPD,
25 resistant smokers and 15 non-smokers) who were subjected to spirometric
measurements, identification of adenovirus C and genotyping of TNF-α –308G/A,
SP-B+1580 C/T and IL-13 –1055 C/T polymorphisms by real-time PCR. 
Results: The adenovirus C gene was identified in all subjects. The distribution
of TNF-α genotypes showed no significant differences between different groups.
However, homozygous A genotype was associated with a significant decrease
in FEV1, FEV1/FVC and FEF25/75% of predicted in COPD (p < 0.05). As regards
SP-B genotypes, resistant smokers had a significantly higher homozygous T
genotype frequency compared to COPD and non smokers (p = 0.005). Inter-
leukin 13 genotypes showed no significant difference between different groups.
There was a significant decrease in FEF25/75% of predicted in T allele carriers
in COPD patients (p = 0.001). 
Conclusions: The COPD is a disease caused by the interaction of combined genes
and environmental influences, in the presence of smoking and latent adenovirus
C infection, TNF-α –308A, SPB +1580 T and IL-13 –1055 T polymorphisms pre-
dispose to the development of COPD. 
Key words: single nucleotide polymorphism, smoking, adenovirus C, chronic obstruc-
tive pulmonary disease.
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex mix of signs
and symptoms in patients with chronic bronchitis and emphysema that
largely results from cigarette smoking [1]. Several lines of evidence strong-
ly suggest that genetic factors influence COPD susceptibility as well; severe 
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α1-antitrypsin deficiency is one of the proven genet-
ic determinants of COPD [2]. Variants in several can-
didate genes have been significantly associated
with COPD, suggesting an interaction between
genetic and environmental influences [3]. 
Transforming growth factor-β1 (TGF-β1) is a rea-
sonable pathophysiological candidate gene which
has been associated with COPD [4]. In a case con-
trol study, the distribution of TGF-β1 genotypes in
an Egyptian population was demonstrated; the
absence of the Pro-Pro alleles in all cases of the
study denoted a high predisposition to COPD in
Egyptian smokers. Moreover, the Pro allele of the
TGF-β1 gene was expressed more commonly in
resistant smokers than in smokers who developed
COPD, demonstrating a protective role against COPD
and an important effect in preserving further decline
in forced expiratory volume in the 1 s (FEV1) [5].
Tumour necrosis factor α (TNF-α), a proinflam-
matory cytokine, has many effects relevant to the
pathogenesis of COPD, including neutrophil release
from the bone marrow and neutrophil activation
[6]. Enhanced levels of TNF-α have been detected
in sputum [7] and in circulation [8] of COPD
patients, indicating that this cytokine is involved in
both the local and systemic inflammation present
in COPD. Analysis of possible TNF-α gene polymor-
phisms in COPD could be related to a higher sus-
ceptibility to develop this disabling pathological con-
dition. An association between the TNF-α –308G/A
polymorphism and COPD was reported in Tai-
wanese [9] and Japanese populations [6].
Surfactant protein B (SP-B) polymorphisms have
been associated with COPD susceptibility in the
presence of a gene-environment interaction [10]. 
Interleukin 13 (IL-13) is strongly implicated in the
development of asthma and COPD, overexpression
of IL-13 in the adult murine lung caused emphyse-
ma, elevated mucus production, and inflammation
reminiscent of human COPD [11]. An increased fre-
quency of the –1055 T allele in COPD patients com-
pared to healthy controls and smokers with normal
lung functions was previously reported, implicating
a functional role of IL-13 promoter polymorphism
in enhanced risk of COPD development [12].
Adenovirus infection is a common cause of bron-
chiolitis in children and young adults [13] that could
predispose to COPD in adulthood [14]. In particular,
group C adenovirus is endemic, and exposure to
infection during childhood could lead to latent infec-
tion that persists in the lung [15], tonsils [16], and
peripheral blood lymphocytes [17]. The COPD is
characterized by cough, sputum production, periph-
eral airways obstruction, and emphysematous
destruction of the lung surface area. All these com-
ponents have been related to an inflammatory
process located in the conducting airways and lung
parenchyma [18].
In this study we aimed to investigate the possi-
ble association of TNF-α –308G/A, SP-B+1580 C/T,
IL-13 –1055 C/T gene polymorphisms and latent
adenovirus infection with COPD in an Egyptian pop-
ulation.
Material and methods
This was a cohort study; all subjects were select-
ed randomly from the Chest Outpatient Clinic and
Pulmonary Function Unit in the National Research
Centre and Chest Department of Cairo University
over 24 months.
Our study included 115 male subjects. Their age
ranged between 40 and 78 years. They were divid-
ed into non-COPD groups, group 1 (non-smokers)
which included 15 non-smoker healthy controls with
normal spirometry and group 2 (resistant smokers)
which included 25 smokers who did not develop
COPD proved clinically and by normal spirometry,
and a COPD group (group 3) which included 
75 smokers with COPD. 
Patients were assigned to the study according
to one or more of the following criteria: age above
40 years, smoking history above 20 pack years, clin-
ical and radiological examination fulfilled the diag-
nostic criteria of COPD [19]. Exclusion criteria includ-
ed diseases other than COPD and working in
industrial areas. All patients gave written informed
consent; the study was approved by the ethical
committee of the National Research Centre. 
All subjects of the study were subjected to med-
ical history taking, clinical examination, plain chest
X-ray postero-anterior view, and pre- and post-bron-
chodilator spirometric measurements of FEV1,
FEV1/FVC (forced vital capacity) and forced expira-
tory flow (FEF) 25/75% of predicted. Normal pul-
monary function test (PFT) was considered as
FEV1% of predicted > 85%, FEV1/FVC % of predict-
ed > 70%. Bronchodilators were stopped 24 h
before PFT.
Thirteen of our COPD patients were admitted to
the ICU for acute (on top of chronic) respiratory fail-
ure, so spirometric measurements were not per-
formed on them.
Laboratory methods
Identification of adenovirus C gene and geno-
typing of TNF-α, SP-B, and IL-13 gene single
nucleotide polymorphisms (SNPs) were done by
real-time polymerase chain reaction (real-time PCR). 
Genomic DNA extraction
Blood samples were collected using EDTA con-
taining blood tubes and treated with sucrose lysis
buffer and the nuclear cell pellets were stored at
–80°C until DNA extraction. Genomic DNA was
extracted from whole blood using the QIAamp
DNA extraction kit (Qiagen Hilden, Germany, Cat
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no. 51304) according to the manufacturer’s instruc-
tions.
Identification of adenovirus C gene by real-time
PCR
The sequence of the Adenovirus C (Adv5) gene
(Bank Accession No: NC_001406) was amplified by
real-time PCR. Primers used were: 
Forward primer 5'GCCATTACCTTTGACTCTTCTGT3',
Reverse primer 5' CCTGTTGGTAGTCCTTGTATT-
TAGTATC3'
and the probe sequence was as follows:
AGAAACTTCCAGCCCATGAGCCG. 
Real-time PCR was conducted using SYBR green
nucleic acid dye in Light Cycler. The reactions were
carried out in a capillary tube with 20 μl reaction vol-
ume containing 7 μl of H2O, 1 μl of forward primer,
1 μl of reverse primer, 9 μl of SYBR green master mix
and 2 μl of extracted DNA. The following thermo-
cycling profile was used for each reaction: 50°C for
2 min to activate uracil N-glycosylase in the master
mix, 95°C for 10 min to activate enzyme followed by
40 cycles of 95°C for 15 s and 60°C for 1 min. Dis-
sociation analysis was run at the end of each SYBR
green real-time PCR reaction to verify a single PCR
amplicon. 
Genotyping of IL-13, SP-B and TNF-α SNPs by
real-time PCR
The studied SNPs were IL-13 –1055 C/T
(rs1800925 in the NCBI, SNP database), surfactant
protein B +1580 C/T (rs2118177), and TNF-α –308 G/A
(rs1800629). The surrounding sequences of these
SNPs were: GGTTTCTGGAGGACTTCTAGGAAAA[C/T]
GAGGGAAGAGCA (VIC/FAMGGAAAAGGCGACA) for
IL-13-1055C/T, CTTTGTCCAGAGGCGACTCCTAACC[C/T]
TTAGCAGGCTCTG (VIC/FAMCCCTAACTTACA) for SP-
B+1580 C/T, and GAGGCAATAGGTTTTGAGGGGCATG
[G/A] GGACGGGGTTC (VIC/FAMAGCCTCCAGGGTCC)
for TNF-α-308 G/A, respectively. To amplify the
regions containing polymorphisms, PCR was con-
ducted for a 40-cycle amplification (10 min at 95°C,
15 s at 92°C and 1 min at 60°C) using 11.25 μl of
genomic DNA diluted in dH2O, 12.5 μl of Taqman
universal PCR Master Mix containing 2.5 mM dNTP,
2.5 mM MgCl2 and 1 unit of Taq polymerase
(Boehringer Mannheim), and 1.25 μl of genotyping
assay mix 20× in each well. 
After amplification, genotyping of polymor-
phisms was carried out using TaqMan SNP geno-
typing assay performed on an Applied Biosystems
7500 Real-Time PCR and ABI PRISM 7000 Sequence
Detection System which is optimized to work with
Taqman universal PCR master mix, and designed
for the allelic discrimination of specific SNPs,
enabling scoring of both alleles in a single well. Soft-
ware automatically determined genotypes and gen-
erated an intuitive graphic representation of results
in a cluster plot report.
Statistical analysis
Statistical Package for Social Sciences (SPSS) ver-
sion 14.0 was used for statistical analysis. The quan-
titative results were expressed as means ± stan-
dard deviation (SD). For comparing quantitative
results between two groups, independent t-test
was used, and for more than two groups ANOVA
and post hoc least significant test (LSD) were used.
Qualitative results were expressed as number (No.)
and percent (%). Pearson chi-square test (χ2) was
used for statistical analysis of the qualitative data.
Differences were considered to be significant when
the p-value was ≤ 0.05.
Results
The study included 115 male subjects. The age
and the smoking history in the resistant smokers
group and COPD patients group were matched
without significant differences (Table I). 
The mean values of the post-bronchodilator FEV1,
FEV1/FVC and FEF25/75% of predicted in COPD
patients group were 47.3%, 59.0% and 29.2%,
respectively. They were significantly lower than in
non-smokers (86.6%, 85.4% and 81.8%, respective-
ly) and resistant smokers (93.1%, 87.7% and 84.4%,
respectively) with value of p < 0.0001 (Table II).
The mean values of the post-bronchodilator 
FEV1, FEV1/FVC and FEF25/75% of predicted nega-
tively correlated with age in COPD patients 
(p < 0.05, p < 0.005 and p < 0.05, respectively). Addi-
tionally, the mean values of the post-bronchodila-
tor FEV1, FEV1/FVC% of predicted negatively corre-
lated with their smoking history (p < 0.01 and 
p < 0.005, respectively) (Table III).
As regards the adenovirus C gene, it was identi-
fied in all subjects of the study (Figure 1). 
The genotype distribution of the TNF-α –308 G/A
polymorphism was heterozygous in 13 cases and
homozygous A in 102 cases. The frequency of the
homozygous A genotype was 90.6% of COPD,
86.7% of non-smokers and 84% of resistant smok-
ers, with no statistical significant difference
between the 3 groups. Homozygous G genotype
was not detected in any of our subjects (Table IV,
Figure 2).
The genotype distribution of the SP-B +1580 C/T
polymorphism showed that the resistant smokers
had a significantly higher frequency of homozy-
gous T than either COPD patients or non-smokers
(p = 0.0050). However, homozygous C genotype 
frequency was higher in COPD patients than in
either resistant smokers or non-smokers, p = 0.005 
(Table IV, Figure 3).
Meanwhile, the genotype distribution of the 
IL-13 –1055 C/T polymorphism showed no signifi-
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cant difference between the studied groups
although there was a high frequency of the
homozygous T genotype in COPD patients (20%)
compared to the resistant smokers (2.8%) and non-
smokers (6.7%) (Table IV, Figure 4). Figure 5 shows
the frequencies of different genotypes in different
studied groups. 
The post-bronchodilator FEV1/FVC% of predict-
ed was significantly decreased in TNF-α homozy-
gous A genotype (86.75) compared to heterozygous
G/A genotype (93.0%) in resistant smokers (p < 0.05)
(Table V).
In COPD patients, there was a statistically sig-
nificant decrease in the mean values of the post-
bronchodilator FEV1, FEV1/FVC and FEF25/75% of
predicted in homozygous TNF-α A genotype (45.3%,
57.6% and 27.4%, respectively) compared to that
in heterozygous G/A genotype (70.2%, 69.4% and
49.8%, respectively), p < 0.05 (Table V). In addition,
the mean values of the post-bronchodilator FEV1
Parameter Group N° Mean ± SD ANOVA
F-ratio Value of p
Age [years] 1 15 57.0 1.51 0.483 NS
2 25 55.3 7.10
3 75 56.7 7.34
Smoking history (pack years) 1 15 0.0 0.00 3.452* NS
2 25 41.6 13.09
3 75 50.1 21.51
*Independent t-test. Group 1 – non-smokers, group 2 – resistant smokers, group 3 – COPD
Table I. Statistical analysis of age (years) and smoking history (pack years) between the 3 groups
Parameter Group N° Mean ± SD ANOVA
F-ratio Value of p LSD
FEV1% 1 15 86.6 22.43 81.128 < 0.0001 (2)
2 25 93.1 10.12 (1,3)
3 62 47.3 17.41 (2)
FEV1/FVC% 1 15 85.4 3.70 62.446 < 0.0001 (2)
2 25 87.7 5.98 (1,3)
3 62 59.0 15.10 (2)
FEF25/75% 1 15 81.8 14.25 109.09 < 0.0001 (2)
2 25 84.4 21.22 (1,3)
3 62 29.2 17.46 (2)
FEV1 – forced expiratory volume in the 1 s, FVC – forced vital capacity, FEF – forced expiratory flow; group 1 – non-smokers, group 2 – resistant
smokers, group 3 – COPD
Table II. Statistical analysis of FEV1%, FEV1/FVC% and FEF25/75% of predicted between the 3 groups
Parameter Group 1G roup 2G roup 3
Age [years]S moking history Age [years]S moking history Age [years]S moking history
FEV1% r –0.3 (a) –0.2 0.2 –0.3 –0.3
Sig. (2-tailed) NS NS NS < 0.05 < 0.01
FEV1/ r 0.2 –0.2 0.3 –0.4 –0.4
FVC%
Sig. (2-tailed) NS NS NS < 0.005 < 0.005
FEF r 0.05 –0.2 0.005 –0.3 –0.2
25/75%
Sig. (2-tailed) NS NS NS < 0.05 NS
(a) Cannot be calculated, smoking history is zero; group 1 – non-smokers, group 2 – resistant smokers, group 3 – COPD
Table III. Correlations between FEV1%, FEV1/FVC% and FEF25/75% of predicted with age (years) and smoking histo-
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and FEV1/FVC% of predicted were significantly
decreased in SP-B homozygous T genotypes (40.9%
and 54.1%, respectively) and homozygous C geno-
type (43.3% and 55.1%, respectively) compared to
those in heterozygous C/T genotype (58.4% and
68.5%, respectively, p < 0.005) (Table VI). Meanwhile,
the mean values of the post-bronchodilator
FEF25/75% of predicted was significantly decreased
in IL-13 homozygous T and C/T genotypes (17.1%
and 27.4%, respectively) compared to homozygous
C genotype (37.6%), p = 0.001 (Table VII).
Discussion
This study selected randomized samples of sub-
jects of the same sex and race. The mean age of
the subjects and their smoking index were statis-
tically matched. All subjects were of Caucasian ori-
gin; it was found that the frequency of an allele can
vary in different racial groups [3]. 
The mean values of the post-bronchodilator FEV1,
FEV1/FVC and FEF25/75% of predicted showed sig-
nificant negative correlations with age and were
significantly reduced in COPD patients compared
to non-COPD groups (p < 0.0001).
Our subjects had a heavy smoking history of
more than 20 pack years. Mean values of the post-
bronchodilator FEV1, FEV1/FVC% of predicted had
significant negative correlations with their smok-
ing history.
Adenovirus C infects more than 80% of the
human population early in life [20]. Moreover, near-
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Parameter Group 1  Group 2  Group 3  χ2 Value of p
(n = 15) (n = 25) (n = 75)
TNF-α –308 G/A (n = 13) Count 2 4 7 0.816* NS
% within groups 13.3 16 9.4
A/A (n = 102) Count 13 21 68
% within groups 86.7 84 90.6
SPB+1580 C/T (n = 41) Count 6 8 27 14.74 0.005
% within groups 40 32 36
T/T (n = 40) Count 4 16 20
% within groups 26.7 64 26.7
C/C (n = 34) Count 5 1 28
% within groups 33.3 4 37.3
IL-13 –1055 C/T (n = 45) Count 5 11 29 3.493 NS
% within groups 33.3 44 38.7
T/T (n = 18) Count 1 2 15
% within groups 6.7 8 20
C/C (n = 52) Count 9 12 31
% within groups 60 48 41.3
*Likelihood ratio
Table IV. Genotype frequencies of TNF-α –308, Surfactant Protein B+1580 and IL-13 –1055 polymorphisms in the 
3 groups
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ly 100% of adults have serum antibody to multiple
serotypes – a finding indicating that infection is
common in childhood [21].
In a study that included 60 children present-
ing with recurrent upper and/or lower respirato-
ry tract infection done in the National Research
Centre of Egypt, it was demonstrated that pas-
sive cigarette smoking remains an enormous
health problem and is a principal cause of recur-
rence of respiratory infections in children, main-
ly adenovirus C infection. High prevalence and
persistence of adenovirus C infection, exceeding
96% of cases, were demonstrated in children by
positive serum IgG and documented by latent
gene expression [22]. 
In our study, identification of adenovirus C in
COPD and non-COPD subjects demonstrated the
persistence of latent infection during childhood and
confirmed our previous study in children. Although
cigarette smoking is the major risk factor for the
development of COPD, only 15% to 20% of all smok-
ers develop airway obstruction [23]. Therefore, ade-
novirus that remains from a previous infection of
the lungs in a smoker may enhance the inflamma-
tory process in their lungs [24]. The correlation
between adenovirus C, COPD and deterioration of
pulmonary function was not demonstrated in this
study, because all included subjects were positive
for adenovirus C and genotyping was not done.
Latent adenoviral infection contributes to chron-
ic airway inflammation through E1A-dependent 
NF-κB (nuclear factor-κβ) activation. It was found
that E1A regulation of the lipopolysaccharide (LPS)
response may play a role in acute exacerbations as
a consequence of bacterial infections in COPD. Ade-
novirus E1A 13S (adenovirus early gene product)
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Figure 2. Allelic discrimination plot of TNF-α –308
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Figure 5. Genotypic frequencies of TNF-α –308, sur-
factant protein B –1580 and IL-13 –1055 genes sin-
gle nucleotide polymorphisms in the 3 groups
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stimulates the TNF gene in inflammatory cell lines.
Moreover, it could contribute to airway remodeling
in COPD by the viral E1A gene, inducing transform-
ing growth factor-β1 (TGF-β1) and connective tis-
sue growth factor (CTGF) expression and shifting
cells to a more mesenchymal phenotype [25].
The TNF-α mediated inflammation is thought to
play a key role in both the respiratory and systemic
features of COPD. Single nucleotide polymorphism
(SNP) in the promoter region of the TNF-α gene
(G→A at position –308) directly affects gene regu-
lation, and is associated with high TNF-α produc-
tion [26].
In the present study, the genotype distribution
of TNF-α –308 polymorphism in Caucasian popula-
tions was heterozygous G/A in 13 cases (11.3%) and
homozygous A in 102 cases (88.7%). Homozygous
alleles G/G were not detected in the studied groups.
The TNF-α –308A allele frequency ranged from 10%
[27] to 17% [28] in the white population, and from
5% [9] to 8% [6] in the Asian population. The pos-
sible cause of this discrepancy may be an ethnic dif-
ference affecting prevalence. 
The study demonstrated no statistically signifi-
cant difference between the 3 groups in the distri-
bution of homozygous A genotype. The heterozy-
gous G/A was present in a higher percentage in the
resistant smoker group compared to the other
groups, with no statistically significant difference
between them. These results were in accordance
with several studies that fail to find an association
between COPD and TNF-α –308G/A polymorphism
in Caucasians [27-32], which might be explained by
variation in genotype frequencies between races,
or by linkage disequilibrium with HLA alleles, seen
previously in the Caucasian population [33].
In contrast to these studies on white subjects,
two studies on Asian subjects showed an associa-
tion of TNF-α –308G/A polymorphism and COPD 
[6, 9]. Alternatively, the allele could be in linkage
disequilibrium with another gene that increases
susceptibility to COPD in smokers only in the Asian
population [34].
On the other hand, the homogenous A genotype
in COPD patients in the current study was accom-
panied by a statistically significant reduction in the
mean values of the post-bronchodilator FEV1,
FEV1/FVC and FEF25/75% of predicted compared to
heterozygous G/A genotypes in COPD (p < 0.05).
Our findings agreed with those of Keatings et al.
[29], who demonstrated that homozygosity for the
A allele predisposes to a worse prognosis for COPD. 
The surfactant proteins are hydrophobic proteins
that contribute to regulation of surface tension in
the alveoli. Components of surfactant also have
a role in host defense and control of inflammation.
Alterations of surfactant might therefore be a fac-
tor in COPD [26].
GroupG enotype N° Mean ± SD T-test Value of p
1 (n = 15) FEV1% G/A 2 90.0 7.07 0.222 NS
A/A 13 86.1 24.10
FEV1/FVC% G/A 2 82.5 2.12 1.21 NS
A/A 13 85.8 3.74
FEF25/75% G/A 2 83.5 6.36 0.175 NS
A/A 13 81.5 15.27
2 (n = 25) FEV1% G/A 4 94.2 12.40 0.212 NS
A/A 21 93.0 9.98
FEV1/FVC% G/A 4 93.0 5.12 2.065 0.05
A/A 21 86.7 5.68
FEF25/75% G/A 4 103.3 22.08 2.06 NS
A/A 21 80.9 19.57
3 (n = 62) FEV1% G/A 5 70.2 6.30 3.312 < 0.005
A/A 57 45.3 16.61
FEV1/FVC% G/A 5 69.4 13.35 2.482 < 0.05
A/A 57 57.6 14.57
FEF25/75% G/A 5 49.8 7.69 2.917 0.005
A/A 57 27.4 16.92
*Likelihood ratio
Table V. Comparison of FEV1%, FEV1/FVC% and FEF25/75% of predicted between different TNF-α –308 genotypes in
the 3 groups
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The genotype distribution of the SP-B +1580 C/T
gene polymorphism showed that the non-smokers
had a higher frequency of the heterozygous C/T geno-
type compared to either resistant smokers or COPD
patients. Meanwhile, resistant smokers had a signif-
icantly higher frequency of T/T genotype, and C/C
genotype was higher in COPD patients (p = 0.005).
The allelic variation of SP-B +1580 between smokers
(C/C and T/T) and non-smokers (C/T) indicates that
these alleles appeared to be “smoking-dependent”.
Moreover, the homozygous alleles (C/C and T/T) were
associated with significant impairment of pulmonary
function in the COPD group compared to that in the
heterozygous alleles (C/T).
In contrast to our findings, Guo et al. [35] in
a Mexican population with COPD reported that the
frequency of the homozygous alleles C/C repre-
sented 49% of cases and the heterozygous alleles
C/T represented 76% of cases. When both marker
alleles were present, the odds ratio (OR) for COPD
was considerably increased (OR = 24.3, p < 0.001)
compared to when both markers were absent. No
significant differences were observed when one
marker was present and the other was absent 
(OR for T = 0.73, p = 0.81; OR for C = 1.9, p = 0.31).
In a study done in a Chinese Han population, it
was concluded that the SP-B 1580 T allele was prob-
ably associated with increased susceptibility to
COPD [36].
In spite of the difference in the distribution of
allelic markers between populations, probably due
to ethnic variation, all studies agreed that 
SP-B+1580 C/T is a smoking-dependent gene which
plays a role in COPD and that the T allele is associ-
ated with deterioration of pulmonary functions. But
in the present study, SP-B homozygous alleles
GroupG enotype N° Mean ± SD F-ratio Value of p
1 (n = 15) FEV1% C/C 5 93.8 7.95 1.098 NS
C/T 6 76.2 33.51
T/T 4 93.3 5.38
FEV1/FVC% C/C 5 85.0 3.32 0.331 NS
C/T 6 84.8 3.31
T/T 4 86.8 5.25
FEF25/75% C/C 5 87.4 18.27 0.987 NS
C/T 6 82.3 14.01
T/T 4 74.0 6.48
2 (n = 25) FEV1% C/C 1 74.6 1.913 NS
C/T 8 93.2 12.34
T/T 16 94.3 8.29
FEV1/FVC% C/C 1 87.2 0.007 NS
C/T 8 87.9 5.11
T/T 16 87.6 6.71
FEF25/75% C/C 1 69.0 1.602 NS
C/T 8 94.8 30.27
T/T 16 80.3 14.19
3 (n = 62) FEV1% C/C 25 43.3 13.92 6.844 <  0.005
C/T 19 58.4 16.13
T/T 18 40.9 18.10
FEV1/FVC% C/C 25 55.1 13.25 6.429 <  0.005
C/T 19 68.5 14.13
T/T 18 54.1 14.48
FEF25/75% C/C 25 24.3 15.37 2.648 NS
C/T 19 36.3 20.14
T/T 18 28.3 15.39
Table VI. Comparison of FEV1%, FEV1/FVC% and FEF25/75% of predicted between different Surfactant Protein B+1580
genotypes in the 3 groups
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(either C/C or T/T) were found to be associated with
worse prognosis of COPD. 
Studies in transgenic mice have shown that the
targeted expression of IL-13 in the adult lung caus-
es emphysema, mucus metaplasia, and inflamma-
tion that mirror, in many ways, the lesions seen in
human COPD. The IL-13 may play an important role
in the pathogenesis of COPD, particularly in
patients with asthma-like features [11].
The distribution of the genotype of IL-13 –1055
C/T polymorphism showed no significant difference
between the studied groups although there was
a higher frequency of homozygous T genotype in
the COPD patient group compared to other groups.
Also, the homozygous T and heterozygous C/T
genotypes were associated with a significant reduc-
tion in the mean values of the post-bronchodilator
FEF25/75% of predicted compared to that in the
case of homozygous C genotype in the COPD group
(p = 0.001). These results indicate that the T allele
is associated with COPD and deterioration of pul-
monary functions. 
Our results are in accordance with those of van
der Pouw Kraan et al., who demonstrated that 
IL-13 promoter region polymorphism –1055 C→T,
associated with increased IL-13 production, is more
common in COPD patients [12].
In conclusion, from our results we concluded that
COPD is a disease caused by the interaction of com-
bined genes and environmental influences. In the
presence of smoking and latent adenovirus C infec-
tion, TNF-α –308G/A, SP-B+1580 C/T and IL-13 –1055
C/T gene polymorphisms predispose to the devel-
opment of COPD and decline of lung functions. 
GroupG enotype N° Mean ± SD F-ratio Value of p
1 (n = 15) FEV1% C/C 9 84.2 28.99 0.135 NS
C/T 5 89.2 6.38
T/T 1 95.0
FEV1/FVC% C/C 9 86.0 2.78 0.275 NS
C/T 5 84.6 5.50
T/T 1 84.0
FEF25/75% C/C 9 82.8 15.99 0.050 NS
C/T 5 80.6 13.92
T/T 1 79.0
2 (n = 25) FEV1% C/C 12 91.8 9.80 0.868 NS
C/T 11 93.1 10.11
T/T 2 102.0 14.14
FEV1/FVC% C/C 12 89.8 6.11 1.471 NS
C/T 11 85.7 5.88
T/T 2 85.9 1.20
FEF25/75% C/C 12 78.0 13.46 1.072 NS
C/T 11 90.4 26.49
T/T 2 90.5 28.99
3 (n = 62) FEV1% C/C 25 43.4 17.58 1.486 NS
C/T 22 52.1 17.45
T/T 15 46.7 16.37
FEV1/FVC% C/C 25 61.8 19.38 1.487 NS
C/T 22 59.5 9.20
T/T 15 53.2 13.07
FEF25/75% C/C 25 37.6 19.48 7.754 0.001
C/T 22 27.4 15.17
T/T 15 17.1 6.11
Table VII. Comparison of FEV1%, FEV1/FVC% and FEF25/75% of predicted between the different IL-13-1055 genotypes
in the 3 groups
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